Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Non-cash Items (2016)

Avalo Therapeutics' Non-cash Items history spans 2 years, with the latest figure at $657099.0 for Q3 2016.

For Q3 2016, Non-cash Items rose 49.47% year-over-year to $657099.0; the TTM value through Sep 2016 reached $657099.0, up 49.47%, while the annual FY2015 figure was $604167.0, N/A changed from the prior year.
Non-cash Items reached $657099.0 in Q3 2016 per AVTX's latest filing, up from $642541.0 in the prior quarter.
In the past five years, Non-cash Items ranged from a high of $657099.0 in Q3 2016 to a low of $439607.0 in Q3 2015.